Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Moore Criteria (Advanced Cervical)

The Moore Criteria identify poor prognostic factors in patients with stage IVB, recurrent, or persistent cervical cancer treated with cisplatin-based chemotherapy.

Evidence-based context for fast calculator use

Purpose:
Moore Criteria predict survival in recurrent or metastatic cervical cancer to guide cisplatin-based chemotherapy regimen selection decisions.
Population:
patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment
Factors:
African American Race?, Performance Status > 0?, Pelvic Disease Present?, Prior Cisplatin use?, Disease-Free Interval < 1 year?
Reference:
Moore DH, et al. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2010;116(1):44-49.
HomeMoore Criteria (Advanced Cervical)
Pin your most used calculators here by clicking the star in the dropdown.

Moore Criteria (Advanced Cervical)

Clinical Context & Background

The Moore Criteria identify poor prognostic factors in patients with stage IVB, recurrent, or persistent cervical cancer treated with cisplatin-based chemotherapy. The score predicts response rate and overall survival.
Primary Source EvidenceMoore DH, et al. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2010;116(1):44-49.
Formula Logic
Sum of 5 risk factors: Black race, PS > 0, Pelvic disease, Prior Cisplatin, DFI < 1 yr.

Reference Data

Risk GroupRisk FactorsMedian Survival
Low Risk0 - 113 months
Intermediate Risk2 - 38 months
High Risk4 - 55 months

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Moore Criteria (Advanced Cervical) when moore Criteria predict survival in recurrent or metastatic cervical cancer to guide cisplatin-based chemotherapy regimen selection decisions.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low Risk through High Risk.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm organ site, pathology, menopausal or postoperative context, imaging, biomarker assay, and specialist referral pathway.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Adnexal-mass, cervical postoperative, endometrial, and ovarian cytoreduction models answer different clinical questions.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment

How to apply this result

For a representative case, verify African American Race?, Performance Status > 0?, Pelvic Disease Present?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Gynecologic Oncology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

FIGO GTN Risk ScoreRMI (Risk of Malignancy Index)ROMA Score (Ovarian)

Frequently Asked Questions

When should Moore Criteria (Advanced Cervical) be used?

Use it for patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment when all required inputs and the intended clinical setting are confirmed.

Can Moore Criteria (Advanced Cervical) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.